ArticleScientific reports2026
Prevalence and associated factors of rifampicin resistance pulmonary tuberculosis among HIV-positive patients in Bahir Dar, Northwest, Ethiopia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) remains a major public health problem and a leading cause of morbidity and mortality among people living with HIV, particularly in high-burden countries such as Ethiopia. TB control is severely compromised by rifampicin-resistant TB (RR-TB) due to limited treatment options and poorer outcomes. This study aimed to determine the prevalence of rifampicin-resistant pulmonary TB and identify associated factors among HIV-positive patients in Bahir Dar, Northwest Ethiopia. An institution-based cross-sectional study was conducted among 174 HIV-positive patients with presumptive pulmonary TB attending tuberculosis clinic in Bahir Dar, Northwest Ethiopia from October to December 2025. Socio-demographic, behavioral, and clinical data were collected using a structured questionnaire and medical record review. Sputum samples were analyzed using the GeneXpert MTB/RIF assay for detection of Mycobacterium tuberculosis and rifampicin resistance. Bivariable and multivariable logistic regression analyses were performed to identify factors associated with rifampicin resistance. Statistical significance was set at p < 0.05. The prevalence of rifampicin resistance was 10.9%; found in 19 out of 174 presumptive TB patients. individuals who were widowed (AOR = 15.9; 95% CI 3.01-83.62) and divorced (AOR = 9.2; 95% CI 1.71-49.88) had considerably greater odds of rifampicin resistance than married people in multivariable analysis. Rifampicin resistance was 2.91 times more likely in participants with previous TB Treatment (95% CI 1.04-8.18, p = 0.042). There was an independent correlation between rifampicin resistance and smoking history (AOR = 3.4; 95% CI 1.02-11.49). The study revealed a high burden of rifampicin-resistant TB among HIV-positive patients in Bahir Dar. Significant predictors of rifampicin-resistant TB included social factors such as marital disruption, behavioral factors like smoking, and advanced HIV disease. Reducing the burden of RR-TB in HIV-infected populations requires strengthening early molecular diagnosis, increasing ART adherence, encouraging smoking cessation, and offering targeted social assistance for vulnerable groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.